Mycobacterium ulcerans vaccine - Swiss TPH Institute/Telormedix

Drug Profile

Mycobacterium ulcerans vaccine - Swiss TPH Institute/Telormedix

Alternative Names: TMX 201 adjuvant-based Buruli ulcer vaccine - Swiss TPH Institute/Telormedix; TMX-201

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Swiss Tropical and Public Health Institute
  • Developer Swiss Tropical and Public Health Institute; Telormedix
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Mycobacterial infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Mycobacterial-infections(Prevention) in Switzerland (Parenteral)
  • 09 Jan 2014 Phase I development is ongoing in Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top